Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to assess the safety, tolerability, and efficacy of rhC1INH
in renal transplant recipients with biopsy-confirmed antibody-mediated rejection (AMR) within
30 days of renal transplantation. This study will combine the investigational drug rhC1INH
with a standard regimen of plasmapheresis (PP) and intravenous immune globulin (IVIG) and
compare this to PP and IVIG alone.